trending Market Intelligence /marketintelligence/en/news-insights/trending/FzSH_PKWGtQvINtQfJydJg2 content esgSubNav
In This List

Health Sciences becomes Immunovant at closure of $395M acquisition

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Health Sciences becomes Immunovant at closure of $395M acquisition

Immunovant Inc., formerly called Health Sciences Acquisitions Corp., has closed its acquisition of Immunovant Sciences in a deal valued at about $395 million.

The merger, announced in October, makes the original Immunovant Sciences a wholly owned subsidiary of the former Health Sciences, the combined company adopting the name Immunovant.

Shareholders of Health Sciences approved the deal at a Dec. 16 meeting, and the new company will trade under the symbol IMVT on Nasdaq.

Immunovant specializes in autoimmune diseases and is developing the drug IMVT-1401 with its partner, HanAll Biopharma.